博瑞医药(688166) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 248,373,219.05, representing a year-on-year increase of 31.53%[5] - Net profit attributable to shareholders was CNY 60,754,391.10, reflecting a growth of 25.00% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 60,315,257.52, up 26.83% year-on-year[5] - The total operating revenue for Q1 2022 was ¥248,373,219.05, an increase from ¥188,839,905.34 in Q1 2021, representing a growth of approximately 31.6%[36] - The total profit for the current period is 65,299,553.52 RMB, an increase from 54,520,921.14 RMB in the previous period, representing a growth of approximately 19.5%[39] - The net profit attributable to shareholders of the parent company is 60,754,391.10 RMB, compared to 48,604,937.62 RMB in the previous period, reflecting an increase of about 25%[39] - Basic and diluted earnings per share for the current period are both 0.15 RMB, up from 0.12 RMB in the previous period, indicating a growth of 25%[41] Cash Flow - The net cash flow from operating activities was negative at CNY -29,648,247.48, a significant decline of 957.37% year-on-year[5] - The company's cash flow from operating activities was impacted by increased R&D and sales promotion expenses, leading to slower cash inflow growth[8] - Cash inflows from operating activities totaled 223,452,577.04 RMB, compared to 217,713,663.33 RMB in the previous period, showing an increase of approximately 2.5%[43] - Cash outflows from operating activities amounted to 253,100,824.52 RMB, compared to 214,255,625.31 RMB in the previous period, representing an increase of about 18.1%[43] - The net cash flow from operating activities is -29,648,247.48 RMB, a decline from 3,458,038.02 RMB in the previous period[47] - Cash inflows from investing activities were 70,266,275.88 RMB, down from 181,262,465.76 RMB in the previous period, indicating a decrease of approximately 61.2%[47] - Cash outflows from investing activities totaled 713,590,475.27 RMB, compared to 407,196,914.90 RMB in the previous period, reflecting an increase of about 75.1%[47] - The net cash flow from financing activities is 664,453,061.70 RMB, compared to 255,955,908.71 RMB in the previous period, showing an increase of approximately 159.7%[47] - The ending balance of cash and cash equivalents is 324,463,902.63 RMB, down from 377,669,961.10 RMB in the previous period[47] Research and Development - Total R&D expenses amounted to CNY 42,737,799.16, which is an increase of 93.19% year-on-year, accounting for 17.21% of total revenue[5][12] - R&D expenses amounted to RMB 42.74 million, a 93.19% increase year-on-year, representing 17.21% of operating revenue[22] - The company submitted 6 domestic patent applications and 2 foreign patent applications during Q1 2022, with a total of 334 patent applications filed to date[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,630,151,545.43, up 22.24% from the previous year[7] - The total assets as of the end of the reporting period were ¥3,630,151,545.43, compared to ¥2,969,615,063.74 at the same time last year, showing a growth of approximately 22.3%[33] - The total liabilities increased to ¥1,749,943,725.24 in Q1 2022 from ¥1,227,980,082.88 in Q1 2021, representing a rise of about 42.5%[33] - The equity attributable to shareholders of the parent company reached ¥1,816,715,512.63, up from ¥1,678,188,732.58 in the previous year, reflecting an increase of approximately 8.3%[33] - Long-term borrowings rose to ¥861,565,706.53 in Q1 2022 from ¥618,693,003.90 in Q1 2021, indicating an increase of about 39.2%[33] Sales Performance - The company's product sales revenue increased by 33.70% year-on-year, while technology revenue surged by 645.14%[8] - Product sales revenue reached RMB 223.47 million, a 33.70% increase compared to the same period last year; technology revenue surged to RMB 17.81 million, a remarkable growth of 645.14%[21] - The revenue from raw material drugs was RMB 207.81 million, with significant growth in specific products: Anifin raw material drug revenue increased by 127.39% and Micafungin raw material drug revenue rose by 83.33%[21] Construction Projects - The construction progress of the Taixing raw material drug and formulation production base is nearing completion, with major structural work finished[23] - The company’s Indonesian project has achieved a construction completion rate of 99.5%, with internal decoration at 98% completion[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,373[13] - The weighted average return on net assets was 3.45%, an increase of 0.11 percentage points compared to the previous year[5]